May 6, 2020 /3BL Media/ - Fondation Botnar and Novartis will support research capacity development in sub-Saharan Africa within the framework of EDCTP’s 2020 Career Development Fellowships. Collectively, the two organisations will contribute up to a maximum of €2.25 million to the initial EDCTP call budget of €1.5 million. Their investments will support successful proposals to conduct research on child and adolescent health with a focus on the interaction between poverty-related infectious diseases and non-communicable diseases.
The impact of the Coronavirus (COVID-19) outbreak continues to disrupt our society as we know it, for many becoming a matter of life or death. While there is ongoing research & development work to identify solutions to address the pandemic, managed or expanded access to medicines is now more critical than ever to help address some of the urgent patient needs at various COVID-19 epicenters.
Partnership with NJPCA, which represents 23 community health centers in NJ, funded 5 telehealth pilots; programs serving as role models for centers across state
The Grant enabled NJ community health centers to quickly implement telehealth to maintain continuity of care for underserved communities, especially critical during the current COVID-19 pandemic
Novartis US Foundation supports programs to reimagine healthcare through use of digital tools to reduce barriers to care
Press Release
Partnership with NJPCA, which represents 23 community health centers in NJ, funded 5 telehealth pilots; programs serving as role models for centers across state
The Grant enabled NJ community health centers to quickly implement telehealth to maintain continuity of care for underserved communities, especially critical during the current COVID-19 pandemic
Novartis US Foundation supports programs to reimagine healthcare through use of digital tools to reduce barriers to care
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease
Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease
Company will also make its hydroxychloroquine intellectual property available to support broad access if medicine is approved for COVID-19
Study complements Novartis commitment to donate up to 130 million doses of hydroxychloroquine globally to support the COVID-19 pandemic response
Novartis has a broad COVID-19 research and development commitment, including multiple large sponsored and investigator initiated clinical trials of its medicines
Press Release
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease
Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease
Company will also make its hydroxychloroquine intellectual property available to support broad access if medicine is approved for COVID-19
Study complements Novartis commitment to donate up to 130 million doses of hydroxychloroquine globally to support the COVID-19 pandemic response
Novartis has a broad COVID-19 research and development commitment, including multiple large sponsored and investigator initiated clinical trials of its medicines
For the first time in history, the global health community is preparing to celebrate World Chagas Disease Day. Novartis is joining the global movement to raise visibility and awareness of patients with Chagas disease1.
Funding and in-kind donations to support local initiatives and communities in the US impacted by the outbreak
Summary:
Funding and in-kind donations to support local initiatives and communities in the US impacted by the outbreak
First grants to focus on immediate need for digital tools and frontline medical organization needs:
USD 250,000 grant to the Commons Project for development of COVIDcheck, a free public digital health service under development with global, national, state and local public health authorities
USD 125,000 grants to each Americares and Direct Relief to support US safety net clinics
US COVID-19 Community Response Fund builds on other Novartis global initiatives to respond to the pandemic, including a USD 20 million Global Response Fund, commitment to donate up to 130 million doses of hydroxychloroquine globally, and participation in industry-wide R&D collaboration with, among others, the Bill & Melinda Gates Foundation
Press Release
Funding and in-kind donations to support local initiatives and communities in the US impacted by the outbreak
First grants to focus on immediate need for digital tools and frontline medical organization needs:
USD 250,000 grant to the Commons Project for development of COVIDcheck, a free public digital health service under development with global, national, state and local public health authorities
USD 125,000 grants to each Americares and Direct Relief to support US safety net clinics
US COVID-19 Community Response Fund builds on other Novartis global initiatives to respond to the pandemic, including a USD 20 million Global Response Fund, commitment to donate up to 130 million doses of hydroxychloroquine globally, and participation in industry-wide R&D collaboration with, among others, the Bill & Melinda Gates Foundation
Collaboration to address product development and scale up challenges posed by current pandemic
Press Release
BASEL, Switzerland, March 26, 2020/3BL Media/ - Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify effective and scalable solutions to the pandemic that is affecting billions worldwide.
Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19
Novartis Sandoz division will pursue appropriate regulatory authorizations and, upon approval, will work with stakeholders to determine how best to get this medicine to the patients who need it
Commitment builds on recently announced USD 20 million Novartis COVID19 Response Fund, drug discovery and development collaborations and essential medicines price stability
Novartis encourages industry, governments and international institutions to work together to ensure adequate global access of medications to treat COVID-19 patients
Press Release
Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19
Novartis Sandoz division will pursue appropriate regulatory authorizations and, upon approval, will work with stakeholders to determine how best to get this medicine to the patients who need it
Commitment builds on recently announced USD 20 million Novartis COVID19 Response Fund, drug discovery and development collaborations and essential medicines price stability
Novartis encourages industry, governments and international institutions to work together to ensure adequate global access of medications to treat COVID-19 patients
March 12, 2020 /3BL Media/ - A diverse group of investors, companies, trade associations, institutions, and organizations across the Northeast and Mid-Atlantic are urging the region’s governors today to band together and create a clean transportation future that enables economic growth.
EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million.
The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance.
The projects will include development of the first new malaria treatment for babies under 5 kg, a new fast-acting medicine for the treatment of severe malaria, and new combinations to treat drug-resistant uncomplicated malaria.
Press Release
EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million.
The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance.
The projects will include development of the first new malaria treatment for babies under 5 kg, a new fast-acting medicine for the treatment of severe malaria, and new combinations to treat drug-resistant uncomplicated malaria.
